Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study.
BACKGROUND
Results of a previous randomized controlled trial comparing the outcome of patients with severe alcoholic hepatitis treated with total enteral nutrition (TEN) or corticosteroids suggest that these treatments act through different mechanisms and may be complementary. We report a pilot study of combined treatment with TEN and a shorter course of steroids in patients with severe alcoholic hepatitis.


METHODS
Thirteen patients with severe alcoholic hepatitis were treated with systemic steroids and TEN. Steroid therapy started with 40 mg oral prednisolone daily, and was progressively tapered as soon as both serum bilirubin and prothrombin time decreased below 50% of their baseline values. TEN (2000 kcal, or 8374 kJ, daily) was administered throughout the hospital stay. Patients were followed for at least 12 months or until death.


RESULTS
Tapering of prednisolone dose could be started after a mean (SD) of 15.4 (3.8) days, whereas TEN was maintained for 22 (3.8) days. TEN was tolerated in 10 of the 13 patients. The major adverse event attributable to therapy was hyperglycemia requiring insulin therapy, which occurred in 12 of 13 patients. Only two patients (15%) died during the treatment period. Another patient died within the first 2 months of follow-up. In no case was the death due to infectious complications, despite two-thirds of patients developing infections during the treatment period. Infections during follow-up occurred only in three patients.


CONCLUSIONS
This pilot study suggests that TEN associated with a short course of steroids could be a good therapeutic strategy for severe alcoholic hepatitis. This possibility deserves investigation in a randomized controlled trial.
Alvarez
Marco A
MA
Department of Gastroenterology, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Cabré
Eduard
E
Lorenzo-Zúñiga
Vicente
V
Montoliu
Silvia
S
Planas
Ramon
R
Gassull
Miquel A
MA
D000328:Adult; D000428:Alcohol Drinking; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D003141:Communicable Diseases / Q000209:etiology; D004334:Drug Administration Schedule; D004750:Enteral Nutrition / Q000009:adverse effects / Q000379:methods*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006519:Hepatitis, Alcoholic / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology; D008103:Liver Cirrhosis / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D013997:Time Factors
D005938:Glucocorticoids; D011239:Prednisolone